Evidence map›Paper›PMID 35871544›Full record

ArticleBrain pathology (Zurich, Switzerland)2023

Atypical TDP-43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP.

Johnathan Cooper-Knock, Thomas H Julian, Emily Feneberg, J Robin Highley, Maurice Sidra, Martin R Turner, Kevin Talbot, Olaf Ansorge, Scott P Allen, Tobias Moll and 8 more

Open access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Johnathan Cooper-KnockSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.ORCID 0000-0002-0873-8689
Thomas H JulianSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Emily FenebergNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0001-5905-3826
J Robin HighleySheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Maurice SidraSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Olaf AnsorgeAcademic Unit of Neuropathology, University of Oxford, Oxford, UK.
Scott P AllenSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Tobias MollSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Tatyana ShelkovnikovaSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Lydia CastelliSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Guillaume M HautbergueSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Christopher HewittSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Janine KirbySheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Stephen B WhartonSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Richard J MeadSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Pamela J ShawSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
University of Sheffield · GBUniversity of Oxford · GBAmarin (United Kingdom) · GBTUM Klinikum · DE

Funding

Biotechnology and Biological Sciences Research Council BB/S005277/1Medical Research Council MR/R024162/1Motor Neurone Disease Association 956-799Motor Neurone Disease Association 972-797Motor Neurone Disease Association 974-797Motor Neurone Disease Association ALLEN/OCT15/956-799Motor Neurone Disease Association NECTAR/OCT15/974-797Motor Neurone Disease Association SHELKOVNIKOVA/OCT17/968-799Motor Neurone Disease Association TURNER/OCT15/972-797Motor Neurone Disease Association TURNER/OCT18/989-797Wellcome TrustWellcome Trust 216596/Z/19/Z
6 · The paper itself

Abstract

We describe an autosomal dominant, multi-generational, amyotrophic lateral sclerosis (ALS) pedigree in which disease co-segregates with a heterozygous p.Y374X nonsense mutation within TDP-43. Mislocalization of TDP-43 and formation of insoluble TDP-43-positive neuronal cytoplasmic inclusions is the hallmark pathology in >95% of ALS patients. Neuropathological examination of the single case for which CNS tissue was available indicated typical TDP-43 pathology within lower motor neurons, but classical TDP-43-positive inclusions were absent from motor cortex. The mutated allele is transcribed and translated in patient fibroblasts and motor cortex tissue, but overall TDP-43 protein expression is reduced compared to wild-type controls. Despite absence of TDP-43-positive inclusions we confirmed deficient TDP-43 splicing function within motor cortex tissue. Furthermore, urea fractionation and mass spectrometry of motor cortex tissue carrying the mutation revealed atypical TDP-43 protein species but not typical C-terminal fragments. We conclude that the p.Y374X mutation underpins a monogenic, fully penetrant form of ALS. Reduced expression of TDP-43 combined with atypical TDP-43 protein species and absent C-terminal fragments extends the molecular phenotypes associated with TDP-43 mutations and with ALS more broadly. Future work will need to include the findings from this pedigree in dissecting the mechanisms of TDP-43-mediated toxicity.

Indexed as

Amyotrophic Lateral SclerosisDNA-Binding ProteinsHumansMutationPedigreeDNA-Binding ProteinsTARDBP protein, humanamyotrophic lateral sclerosisgeneticsneuropathologyprotein aggregationTDP-43

Identifiers

PMID35871544
PMCPMC9836368
OpenAlexW4286945924

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.